Mounjaro®
Starting from £179.99/mo
Start journey Learn moreRybelsus and Wegovy side by side: same molecule, very different medicines
You're already on semaglutide, so why does the licence matter?
Picture the situation: you've been managing blood sugar with Rybelsus tablets, your weight has also shifted a little, and now the conversation with your clinician has turned to whether Wegovy might be the right next step. It feels like a small administrative change. It isn't.
Rybelsus (3mg, 7mg, 14mg tablets) is licensed in the UK exclusively for type 2 diabetes. The NHS medicines page for semaglutide is clear on this: Rybelsus is not authorised for weight management, and prescribing it for that purpose would be off-licence. Wegovy, by contrast, carries a specific UK weight-management licence, for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure or raised cholesterol. The same active ingredient, semaglutide, but a different indication, different dose ceiling and a different regulatory pathway.
This distinction also shapes what a prescriber can lawfully do. You can explore what's licensed for weight loss in the UK on the weight-loss treatment overview.
The doses don't match up, and that gap matters more than you'd think
Rybelsus tops out at 14mg daily. Wegovy's maintenance dose is 2.4mg weekly, or, since the MHRA approved a dedicated 7.2mg pen in April 2026, up to 7.2mg weekly for eligible patients. The numbers look smaller for Wegovy, but semaglutide absorbed via injection behaves differently from the oral route: bioavailability is higher, the dose-to-effect relationship is not a straight translation, and the titration schedule starts again from scratch.
Wegovy's standard injection pathway runs from 0.25mg weekly, stepping up roughly every four weeks through 0.5mg, 1.0mg, 1.7mg and 2.4mg. Anyone moving from Rybelsus to Wegovy does not jump straight to a higher injectable dose, the titration serves a real physiological purpose, managing GI side effects as your system adjusts to a new delivery mechanism. Your prescriber decides where any switch begins.
For those curious about how the oral formulation compares to the injection in more detail, the Wegovy tablets page covers the absorption mechanism and storage differences, including, notably, that the tablet needs an empty stomach and a wait of at least 30 minutes before your morning coffee, while the injection pen lives in the fridge door alongside your other temperature-sensitive items.
What the evidence says about each form, and what that means for switching
The comparison table below draws from published trial data. Both are the same molecule; the differences lie in dose ceilings, route and studied populations.
| Factor | Rybelsus (oral semaglutide) | Wegovy injection (semaglutide) |
|---|---|---|
| UK licence | Type 2 diabetes only | Weight management (BMI ≥30, or ≥27 + condition) |
| Dose range | 3mg, 7mg, 14mg daily | 0.25mg–2.4mg weekly (up to 7.2mg for eligible patients) |
| Average weight reduction in trials | Not studied for weight loss; diabetes trials showed modest weight reduction as a secondary outcome | Around 15% average over 68 weeks at 2.4mg in STEP 1 [NEJM, STEP 1] |
| NICE recommendation for weight loss | None | TA875, within specialist weight management services, up to 2 years [NICE TA875] |
| Administration | Once daily tablet, empty stomach, plain water only for ≥30 min after | Once-weekly subcutaneous injection |
The STEP 1 trial enrolled adults with obesity but without diabetes; Rybelsus trials enrolled people with type 2 diabetes, so direct weight-outcome comparisons between the two products are not straightforward. A prescriber weighs your full medical picture, not just these headline figures.
What IS licensed for weight loss in the UK, and how nume routes you there
If weight management is the goal, two medicines hold UK marketing authorisations for that purpose: Wegovy (semaglutide by injection, and now the Wegovy tablet approved in June 2026 as the first oral GLP-1 for weight loss in the UK) and Mounjaro (tirzepatide, a dual GIP and GLP-1 receptor agonist). Rybelsus is not on that list. Neither is Ozempic, which is also semaglutide but licensed for diabetes, a distinction the semaglutide tablets vs Ozempic comparison covers in full.
At nume, our prescribers can assess suitability for Wegovy or Mounjaro through a free consultation. If you're currently on Rybelsus, being transparent about that in your consultation is important: the prescriber needs to know what you're already taking, at what dose and for what reason, before making any recommendation. The Rybelsus vs semaglutide explainer covers the licensing distinction in more depth if you want the full picture before your consultation.
Which option suits you is a clinical decision our prescribers make with you, based on your health history, current medicines and what you're hoping to achieve, and if you'd like to understand how oral semaglutide compares to traditional diabetes medicines before that conversation, we have a full breakdown available. You can also review what Wegovy pills cost so you have a clear sense of the investment involved. Check your eligibility with a free consultation.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.